Trade

with

Sunesis Pharmaceuticals Inc
(NASDAQ: SNSS)
AdChoices
1.44
+0.01
+0.70%
After Hours :
-
-
-

Open

1.42

Previous Close

1.43

Volume (Avg)

193.45k (2.08M)

Day's Range

1.42-1.46

52Wk Range

1.00-8.46

Market Cap.

85.83M

Dividend Rate ( Yield )

-

Beta

2.52

Shares Outstanding

60.44M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 7.96M

    • Net Income

    • -34.60M

    • Market Cap.

    • 85.83M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -516.68

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.52

    • Forward P/E

    • -2.74

    • Price/Sales

    • 10.27

    • Price/Book Value

    • 5.61

    • Price/Cash flow

    • -2.04

      • EBITDA

      • -31.66M

      • Return on Capital %

      • -74.56

      • Return on Equity %

      • -818.42

      • Return on Assets %

      • -74.56

      • Book Value/Share

      • 0.26

      • Shares Outstanding

      • 60.44M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 3.70

        • Credit Rating

        • -

        • Analysts

        • 5

        • EPS Estimate

        • -0.62

        • Cashflow Estimate

        • -0.73

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 7.99

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -516.68

            • 39.38

            • Net Profit Margin

            • -516.68

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -15,626.20

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.27

              • 0.76

              • Current Ratio

              • 1.51

              • 2.92

              • Quick Ratio

              • 1.48

              • 2.35

              • Interest Coverage

              • -16.62

              • 38.02

              • Leverage Ratio

              • 3.77

              • 2.21

              • Book Value/Share

              • 0.26

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.99

                • 277.78

                • P/E Ratio 5-Year High

                • -19.70

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.35

                • 124.82

                • Price/Sales Ratio

                • 10.27

                • 9.35

                • Price/Book Value

                • 5.61

                • 8.50

                • Price/Cash Flow Ratio

                • -2.04

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -818.42

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -74.56

                    (-202.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -169.30

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.14

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -31.77M
                  Operating Margin
                  -399.36
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -2.04
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  80.54%

                  Mutual Fund Ownership

                  30.76%

                  Float

                  61.64%

                  5% / Insider Ownership

                  3.19%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    3,100,478

                  • 6.54

                  • 5.13

                  • T. Rowe Price Health Sciences Fund

                  •  

                    2,024,800

                  • -0.32

                  • 3.36

                  • Eagle Small Cap Growth Fund

                  •  

                    1,920,448

                  • 80.23

                  • 3.18

                  • Vanguard Total Stock Mkt Idx

                  •  

                    846,347

                  • 0.00

                  • 1.40

                  • iShares Russell 2000 (AU)

                  •  

                    767,763

                  • -0.89

                  • 0.26

                  • UBS (Lux) EF Biotech (USD)

                  •  

                    664,900

                  • 0.00

                  • 1.10

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    602,217

                  • 35.87

                  • 1.00

                  • AXA Framlington Biotech

                  •  

                    591,155

                  • 0.00

                  • 1.00

                  • Fidelity® Small Cap Growth Fund

                  •  

                    550,600

                  • 17.00

                  • 0.91

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    5,893,898

                  • -4.40%

                  • 9.79

                  • NEA Management Company, LLC

                  •  

                    5,636,573

                  • 0.00%

                  • 9.36

                  • RA Capital Management, LLC

                  •  

                    4,869,261

                  • 0.00%

                  • 8.09

                  • Visium Asset Management LLC

                  •  

                    4,526,750

                  • 0.00%

                  • 7.52

                  • Eagle Asset Management, Inc.

                  •  

                    2,342,041

                  • +100.94%

                  • 3.87

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Sunesis Pharmaceuticals, Inc., was incorporated in the state of Delaware on February 10, 1998. It is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid...more and hematologic cancers. It currently focuses on the development of vosaroxin for the treatment of acute myeloid leukemia, or AML. Vosaroxin is a first-in-class anti-cancer quinolone derivative, or AQD—a class of compounds that has not been used previously for the treatment of cancer. AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. It has built an experienced cancer drug development organization committed to advancing vosaroxin in multiple indications to improve the lives of people wit...moreh cancer. In December 2010, the Company commenced enrollment of a Phase 3, multi-national, randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial. The VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, a widely used chemotherapy in AML, on overall survival as compared to placebo in combination with cytarabine. The Company owns development and commercialization rights to vosaroxin. It faces competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching, developing and marketing products designed to address the treatment of cancer, including AML and ovarian cancer. In addition to regulations in the United States, the Company is subject to foreign regulations governing clinical trials and commercial sales and distribution of vosaroxin or its future drug candidates, if any.lessless

                  Key People

                  Daniel N. Swisher,Jr

                  CEO/President/Director

                  James W. Young,PhD

                  Chairman of the Board/Director

                  Eric H. Bjerkholt

                  CFO/Chief Accounting Officer/Executive VP, Divisional/Secretary

                  Adam R. Craig

                  Chief Medical Officer/Executive VP, Divisional

                  Joseph I. DePinto

                  Executive VP/Other Executive Officer

                  • Sunesis Pharmaceuticals Inc

                  • 395 Oyster Point Boulevard

                  • South San Francisco, CA 94080

                  • USA.Map

                  • Phone: +1 650 266-3500

                  • Fax: +1 650 266-3501

                  • sunesis.com

                  Incorporated

                  1998

                  Employees

                  32

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: